The Cheapest Legitimate Path to Tirzepatide, September 2026
We exclude providers carrying FDA warning letters from lowest-cost positions on principle. Here is what the cheapest defensible option actually is once you apply that filter.
Bottom line
- Among providers we list without a regulatory flag, the lowest verified compounded oral tirzepatide prices are MadeMed at approximately $229/month and Wellorithm at $249/month.
- Sprout Health's compounded oral tirzepatide at $249–$299/month carries FDA warning letter #715879 and is excluded from our lowest-cost position.
- There is no approved oral tirzepatide. Tirzepatide's approved forms are injectable.
- The compounding wind-down applies to tirzepatide specifically — price this route with transition risk included.
Cheapest is an easy question to answer badly. Sorting a list by price and publishing the top row takes no work and routinely points people at the providers with the most regulatory problems, because regulatory corner-cutting is one of the ways a price gets low.
Our rule: providers carrying FDA warning letters are listed with the letter disclosed, and excluded from featured and lowest-cost positions regardless of what they pay us. Here is what tirzepatide looks like with that filter applied.
The unflagged options
Compounded tirzepatide, no regulatory flag
| Provider | Form | Price recorded | Notes |
|---|---|---|---|
| MadeMed | Oral | ~$229/mo | Lowest unflagged verified price |
| Wellorithm | Oral tablets | $249/mo | Also offers oral semaglutide at $147/mo |
| Care Bare Rx | Oral / injectable | Not verified | Oral pathway exists in intake; we have not verified current pricing |
All compounded. Compounded drug products are not FDA-approved. Prices exclude any separately charged consultation or membership fees.
The flagged options, disclosed
Providers we list with regulatory flags attached
| Provider | Price recorded | Flag |
|---|---|---|
| Sprout Health | $249–$299/mo oral tirz | FDA warning letter #715879 |
Disclosed on every appearance on this site. Excluded from featured and lowest-cost positions. Listed because omitting it would give you an incomplete view of the market, not because we recommend it.
If we removed them, you would see a market that appears cleaner than it is, and you would encounter these providers elsewhere without the context. Showing them with the letter attached gives you more information than hiding them does. What we will not do is put them in a position that implies a recommendation.
The thing most tirzepatide shoppers miss
There is no FDA-approved oral tirzepatide. Every oral tirzepatide product in the table above is compounded. The approved oral GLP-1 options are semaglutide-based — the Wegovy pill, approved December 2025 — and orforglipron, a different molecule entirely, approved as Foundayo on April 1, 2026.
So the comparison people usually want to make — cheap oral tirzepatide versus expensive brand tirzepatide — is not comparing two versions of the same thing. It is comparing an unapproved compounded formulation against an approved injectable.
Verify current tirzepatide pricing
All providers below are paid partners. Prices shown were recorded at publication and change without notice — always confirm on the provider's own page before you enrol.
Compounded oral tablets. Lowest verified oral semaglutide price among providers we list without a regulatory flag.
Check current pricing Paid partner linkSublingual semaglutide and oral tirzepatide, compounded.
Check current pricing Paid partner linkCash-pay marketplace for appointments with clinicians who prescribe FDA-approved brand-name medication only. No compounded product.
Check current pricing Paid partner linkTirzepatide-focused telehealth program.
Check current pricing Paid partner linkTransition risk belongs in the price
Tirzepatide is named specifically in the wind-down. Following resolution of the shortage, 503A pharmacies were given until February 18, 2025 and 503B outsourcing facilities until March 19, 2025 to wind down mass tirzepatide compounding. On April 30, 2026 the FDA proposed removing tirzepatide, along with semaglutide and liraglutide, from the 503B Bulks List entirely.
Eli Lilly sued compounders Strive Pharmacy and Empower in April 2025 over compounded tirzepatide products, and four telehealth companies weeks later. Lilly's complaint against Strive specifically concerned tirzepatide formulations with additives such as vitamin B12 or glycine.
A March 2026 analysis identified a tirzepatide-B12 adduct in mass-compounded tirzepatide formulated with B12 — a molecular species not present in FDA-approved tirzepatide. If your compounded tirzepatide contains B12, ask your pharmacy for the full formulation and a certificate of analysis for your lot.
Our actual answer
Among providers we list without a regulatory flag, MadeMed's oral tirzepatide at roughly $229 per month is the lowest verified price, with Wellorithm at $249 close behind.
Whether that is the right purchase is a different question from whether it is the cheapest one. You are buying an unapproved compounded formulation of a molecule that is the specific target of an active FDA rulemaking and multiple manufacturer lawsuits, at a price roughly $80 per month above an approved oral GLP-1 with a manufacturer-controlled supply chain. That trade is defensible if tirzepatide specifically is what you and your clinician want. It is not obviously correct on price alone.
Sources & price verification
- Provider pricing recorded from partner program data, September 2026.
- FDA warning letter #715879 (Sprout Health).
- FDA shortage resolution and 503A / 503B tirzepatide wind-down deadlines of February 18 and March 19, 2025.
- FDA proposed action on 503B Bulks List status, April 30, 2026.
- Reporting on Eli Lilly litigation against Strive Pharmacy and Empower over compounded tirzepatide formulations.
- March 2026 analytical study identifying a tirzepatide-B12 adduct in compounded product.
- AJMC, reporting on Foundayo approval and pricing.